5 Key Takeaways

• 1

  Dr. Amir H. Shojaei is the chief scientific officer at Harrow, overseeing medical, clinical, and regulatory affairs.

• 2

  Vevye, launched in January 2024, shows sustained efficacy and good tolerability for dry eye disease, with minimal patient discomfort.

• 3

  The Vevye Access for All initiative reduces barriers to therapy by offering affordable access and simplifying prescription processes.

• 4

  Harrow's partnership with Cencora enhances accessibility and affordability for retinal products like Iheezo and Triesence.

• 5

  Triesence, now under Harrow's management, will have expanded reimbursement starting April 1, 2025, improving patient access.